GET DAILY SIGNALSAstraZeneca (AZN) Reports Q3 Revenue Up 7% and Core EPS Rising 17%
Key Takeaways
- Total revenue rose 7% year over year to $16.21 billion, ahead of the roughly $16.0 billion consensus estimate.
- Core earnings per share (EPS) climbed 17% to $2.79, beating the consensus estimate of about $2.60 per share.
- Oncology led the way with 17% sales growth, powered by double-digit gains from Tagrisso, Imfinzi, Calquence, and Enhertu.
- AstraZeneca reaffirmed its full-year 2026 guidance for mid-to-high single-digit revenue growth and low double-digit Core EPS growth at constant exchange rates.
- The company launched a new restructuring program, "Reshaping for Sustainable Growth," targeting $1.5 billion in annual pre-tax savings by the end of 2029.
- For more on the stock, explore Major News, Today's Price Move, Price Targets, and Forecast on additional pages.
- Discover automated insights by exploring Trending AI Robots.
Why This Quarter Matters for AstraZeneca Investors
AstraZeneca's third-quarter report matters because it tests whether the pharmaceutical giant can keep growing while managing patent expirations and pricing pressure in key markets. The company has faced recent trial setbacks and earlier media speculation about merger discussions, making a clean quarter an important signal of execution. Investors are also watching whether its diversified therapy areas — oncology, respiratory and immunology, and rare diseases — can offset declining sales of older medicines like Farxiga and Brilinta. With a pipeline of more than 180 projects and a wave of late-stage readouts expected in 2027, this quarter helps confirm whether AstraZeneca remains on track toward its long-term growth ambitions. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
The Quarter's Reported Figures
AstraZeneca reported third-quarter 2026 total revenue of $16.21 billion, up 7% from the prior year at both actual and constant exchange rates (CER). Core EPS reached $2.79, a 17% increase on an actual basis and 19% at CER, while reported EPS rose 23% to $2.02. Both top and bottom lines came in above analyst expectations, with revenue beating the consensus estimate of about $16.0 billion and Core EPS exceeding the roughly $2.60 consensus.
Profit attributable to owners of the parent climbed to $3.12 billion from $2.53 billion a year earlier. Oncology was the standout, growing 17%, while respiratory and immunology and rare disease also delivered solid gains. These advances helped offset headwinds from the loss of exclusivity on Farxiga and Brilinta and volume-based procurement in China. The company reaffirmed its fiscal 2026 outlook, expecting mid-to-high single-digit revenue growth and low double-digit Core EPS growth at CER, with a core tax rate of 18–22%.
Investor Reaction to the Results
Markets responded positively to the results, with AstraZeneca shares trading higher in London on the morning of the release. Investors appeared to welcome the earnings and revenue beat, the reaffirmed guidance, and evidence that growth in oncology and rare disease is compensating for pressures elsewhere in the portfolio. The results also helped reassure the market after a period of turbulence tied to earlier trial failures and merger speculation. Attention now turns to the company's execution of its restructuring program and the large pipeline readouts expected in 2027.
Outlook and What to Watch Next
AstraZeneca enters the final quarter of 2026 with its full-year guidance intact, signaling confidence that momentum can continue. The newly announced "Reshaping for Sustainable Growth" program will be a key area to watch. It is expected to involve up to $2 billion in one-time restructuring costs over three years while delivering $1.5 billion in annual pre-tax savings by the end of 2029, with resources redirected toward the pipeline and emerging technologies.
Investors should monitor how management balances those restructuring costs against margin expectations, particularly as research and development spending continues to rise with a larger number of late-stage trials. The company's oncology franchise, led by Tagrisso, Imfinzi, Calquence, and Enhertu, remains central to near-term growth, while declines in cardiovascular, renal, and metabolism products tied to patent expirations will need to be absorbed.
Looking ahead, the 2027 clinical catalyst calendar is a major focus. Management has highlighted upcoming readouts with a collective peak-year revenue potential of more than $20 billion, including the anticipated anti-cancer AVANZAR trial. The October completion of a $2 billion equity investment in Summit Therapeutics and collaborations with Daiichi Sankyo also add strategic dimensions to watch. As always, investors should track how pipeline progress, pricing dynamics in China, and foreign-exchange movements shape results in the quarters ahead.
How Tickeron Tools Support My Research
In my own workflow, I often turn to Tickeron’s AI Screener when reviewing earnings seasons like this one. It helps me quickly filter peers and spot patterns across the sector without spending hours on manual screens. The platform’s AI-driven signals and customizable filters give a clearer picture of where a name like AZN stands relative to the broader group, which I find useful for confirming my thesis before adjusting positions.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
AZN in upward trend: 10-day moving average moved above 50-day moving average on October 21, 2026
The 10-day moving average for AZN crossed bullishly above the 50-day moving average on October 21, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 12 of 16 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 75%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 14, 2026. You may want to consider a long position or call options on AZN as a result. In 50 of 79 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 63%.
The Moving Average Convergence Divergence (MACD) for AZN just turned positive on October 15, 2026. Looking at past instances where AZN's MACD turned positive, the stock continued to rise in 25 of 42 cases over the following month. The odds of a continued upward trend are 60%.
AZN moved above its 50-day moving average on October 14, 2026 date and that indicates a change from a downward trend to an upward trend.
Following a +10.11% 3-day Advance, the price is estimated to grow further. Considering data from situations where AZN advanced for three days, in 190 of 335 cases, the price rose further within the following month. The odds of a continued upward trend are 57%.
Bearish Trend Analysis
The RSI Oscillator demonstrated that the stock has entered the overbought zone. This may point to a price pull-back soon.
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 10 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where AZN declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 46%.
AZN broke above its upper Bollinger Band on October 30, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron Profit vs. Risk Rating rating for this company is 14 (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 60, placing this stock better than average.
The Tickeron Price Growth Rating for this company is 39 (best 1 - 100 worst), indicating steady price growth. AZN’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 44 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Valuation Rating of 62 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (5.756) is normal, around the industry mean (-1.403). P/E Ratio (27.693) is within average values for comparable stocks, (21.451). Projected Growth (PEG Ratio) (1.168) is also within normal values, averaging (5.738). Dividend Yield (0.023) settles around the average of (0.039) among similar stocks. P/S Ratio (4.148) is also within normal values, averaging (4.033).
The Tickeron PE Growth Rating for this company is 66 (best 1 - 100 worst), pointing to average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a manufacturer of pharmaceutical products
Industry PharmaceuticalsMajor
Advertisement